Hydroxyurea

S. Cortelazzo, G. Finazzi, M. Ruggeri, O. Vestri, M. Galli, F. Rodeghiero

Hydroxyurea for patients with Essential Thrombocythemia and a high risk of thrombosis

The New England Journal of Medicine 1995; 332: 1132-6.

G. Finazzi, V. Caruso, R. Marchioli, G. Capnist, T. Chisesi, C. Finelli

Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study

Blood 2005; 105: 2664-2670

Y. Najean ,J.-D. Rain

Treatment of Polycythemia Vera: The Use of Hydroxyurea and Pipobroman in 292 Patients Under the Age of 65 Years

Blood 1997; 90(9): 3370-337

J. L.Spivak, H.Hasselbalch

Hydroxycarbamide: a user’s guide for chronic myeloproliferative disorders

Expert Rev. Anticancer Ther.2011; 11(3): 403–414

J. L. Spivak

An inconvenient truth

Blood 2010; 115(14): 2727-2728

N. H. Thoennissen, U. O. Krug, D. H. T. Lee, N. Kawamata, G. B. Iwanski, T. Lasho

Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome–negative myeloproliferative neoplasms

Blood 2010; 115(14): 2882-2890

A. Weinfeld, B. Swolin , J. Westin

Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: Prospective study of efficacy and leukaemogenicity with therapeutic implications

Eur J Haematol 1994: 52: 134-139.